Stockscreener 앱 받기
160.08
0.36%
0.6575
전일 마감가:
$159.42
열려 있는:
$162.2
하루 거래량:
132.60K
Relative Volume:
0.76
시가총액:
$6.00B
수익:
-
순이익/손실:
$-32.61M
주가수익비율:
-136.33
EPS:
-1.1742
순현금흐름:
-
1주 성능:
-0.51%
1개월 성능:
+6.67%
6개월 성능:
+169.07%
1년 성능:
+172.48%
1일 변동 폭
$157.35
$162.49
1주일 범위
$153.56
$162.49
52주 변동 폭
$49.00
$169.75
Belite Bio Inc Adr Stock (BLTE) Company Profile
BLTE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
160.00 | 5.98B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.32 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.53 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.23 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
804.32 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.16 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-11-20 | 개시 | Mizuho | Neutral |
| 2023-12-14 | 개시 | Maxim Group | Buy |
| 2023-07-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 개시 | SVB Securities | Outperform |
| 2022-08-01 | 개시 | H.C. Wainwright | Buy |
| 2022-07-01 | 개시 | The Benchmark Company | Buy |
모두보기
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target - Investing.com
Belite Bio (NASDAQ:BLTE) Lowered to Sell Rating by Wall Street Zen - Defense World
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighTime to Buy? - MarketBeat
Behavioral Patterns of BLTE and Institutional Flows - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Shares Up 5.5%Should You Buy? - MarketBeat
Belite Bio stock hits all-time high at 163.25 USD - Investing.com
Belite Bio stock hits all-time high at 163.25 USD By Investing.com - Investing.com Australia
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Short Interest Down 45.2% in December - MarketBeat
Belite Bio (NASDAQ:BLTE) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
The $100 ClubWere You Early To The Triple-Digit Rally In ABVX, NUTX, BLTE…? - RTTNews
(BLTE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Sets New 1-Year HighHere's Why - MarketBeat
Can Belite Bio Inc (Common Stock) (D01) stock attract analyst upgradesMarket Movers & Expert Approved Trade Ideas - Улправда
Belite Bio, IncDepositary Receipt (BLTE) Price Target Increased by 21.98% to 116.02 - MSN
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Belite Bio (NASDAQ:BLTE) Sets New 52-Week High – Here’s What Happened - Defense World
Belite Bio Shares Surge After Landmark Phase 3 Success in Stargardt Disease - MSN
Belite Bio (NASDAQ:BLTE) Reaches New 52-Week HighShould You Buy? - MarketBeat
Belite Bio stock hits all-time high at 160.74 USD - Investing.com
Belite Bio stock hits all-time high at 160.74 USD By Investing.com - Investing.com Canada
Price-Driven Insight from (BLTE) for Rule-Based Strategy - news.stocktradersdaily.com
Belite Bio (NASDAQ:BLTE) Stock Price Down 5.9%Should You Sell? - MarketBeat
Belite Bio (NASDAQ:BLTE) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Analysts’ Opinions Are Mixed on These Consumer Goods Stocks: Clene (CLNN) and Costco (COST) - The Globe and Mail
Belite Bio (NASDAQ:BLTE) Rating Increased to Outperform at Mizuho - MarketBeat
FY2025 EPS Estimates for Belite Bio Lowered by HC Wainwright - MarketBeat
Belite Bio (NASDAQ:BLTE) Raised to “Outperform” at Mizuho - Defense World
Belite Bio prices 2.27M ADSs at $154.00 to raise $350M in public offering - MSN
Belite Bio (NASDAQ:BLTE) Shares Gap UpWhat's Next? - MarketBeat
Belite Bio stock price target raised to $187 from $132 at Benchmark By Investing.com - Investing.com South Africa
Belite Bio stock price target raised to $187 from $132 at Benchmark - Investing.com Nigeria
Is Belite Bio’s Surge Justified by DCF Upside and Price to Book Signals? - Sahm
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of “Hold” by Brokerages - Defense World
Belite Bio Reports Increased Cash Reserves Amid Rising R&D Costs - The Globe and Mail
Belite Bio Prices $350 Million ADS Offering to Boost Drug Development - TipRanks
Does Belite Bio Inc ADR (BLTE) offer a good opportunity for investors? - Setenews
Mizuho upgrades Belite Bio stock to Outperform on positive trial data By Investing.com - Investing.com South Africa
Mizuho upgrades Belite Bio stock to Outperform on positive trial data - Investing.com Australia
Why Belite Bio’s Stock is Making Waves - TipRanks
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Belite Bio prices public offering of ADSs at $154 each - Investing.com
Belite Bio prices public offering of ADSs at $154 each By Investing.com - Investing.com India
Belite Bio (NASDAQ: BLTE) prices $350M ADS offer to back commercialization, pipeline - Stock Titan
Belite Bio Announces Pricing of $350.0 Million Underwritten Public Offering of American Depositary Shares - GlobeNewswire Inc.
Belite Bio Inc Adr (BLTE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.47%
0.03%
자본화:
|
볼륨(24시간):